XML 41 R18.htm IDEA: XBRL DOCUMENT
v3.25.3

Segments of business and geographic areas | 9 Months Ended
--- | ---
Sep. 28, 2025
Segment Reporting [Abstract] |
Segments of business and geographic areas | Segments of business and geographic areas The Company is organized into two business segments: Innovative Medicine and MedTech. The Company’s chief operating decision maker (CODM) is the Chief Executive Officer (Principal Executive Officer). For the Innovative Medicine and MedTech segments, the CODM uses segment income before tax to allocate resources (including employees, financial, and capital resources) for each segment predominantly in the annual forecasting process. The CODM considers planning-to-actual variances on a quarterly basis to assess performance and make decisions about allocating resources to the segments. Sales by segment of business
|  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended
(Dollars in Millions) |  | September 28, 2025 |  | September 29, 2024 |  | Percent Change |  | September 28, 2025 |  | September 29, 2024 |  | Percent Change
INNOVATIVE MEDICINE |  |  |  |  |  |  |  |  |  |  |  |
Oncology |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | $3,468 |  | 2,816 |  | 23.2 | % |  | $9,866 |  | 7,835 |  | 25.9 | %
International |  | 3,060 |  | 2,565 |  | 19.3 |  |  | 8,652 |  | 7,450 |  | 16.1 |
Worldwide |  | 6,529 |  | 5,380 |  | 21.3 |  |  | 18,519 |  | 15,284 |  | 21.2 |
CARVYKTI |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 396 |  | 258 |  | 53.3 |  | 1,072 |  | 565 |  | 89.6
International |  | 128 |  | 27 |  | * |  | 260 |  | 63 |  | *
Worldwide |  | 524 |  | 286 |  | 83.5 |  | 1,332 |  | 629 |  | *
DARZALEX |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 2,088 |  | 1,684 |  | 24.0 |  |  | 5,934 |  | 4,789 |  | 23.9 |
International |  | 1,584 |  | 1,332 |  | 18.9 |  |  | 4,514 |  | 3,797 |  | 18.9 |
Worldwide |  | 3,672 |  | 3,016 |  | 21.7 |  |  | 10,448 |  | 8,586 |  | 21.7 |
ERLEADA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 378 |  | 337 |  | 12.3 |  |  | 1,048 |  | 940 |  | 11.5 |
International |  | 558 |  | 453 |  | 23.0 |  |  | 1,567 |  | 1,275 |  | 22.9 |
Worldwide |  | 936 |  | 790 |  | 18.4 |  |  | 2,615 |  | 2,215 |  | 18.0 |
IMBRUVICA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 211 |  | 259 |  | (18.3) |  |  | 685 |  | 770 |  | (11.0) |
International |  | 483 |  | 494 |  | (2.3) |  |  | 1,453 |  | 1,537 |  | (5.4) |
Worldwide |  | 695 |  | 753 |  | (7.8) |  |  | 2,139 |  | 2,307 |  | (7.3) |
RYBREVANT/ LAZCLUZE(1) |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 136 |  | 68 |  | 99.7 |  | 388 |  | 156 |  | *
International |  | 61 |  | 21 |  | * |  | 130 |  | 49 |  | *
Worldwide |  | 198 |  | 89 |  | * |  | 518 |  | 205 |  | *
TALVEY |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 85 |  | 64 |  | 34.2 |  |  | 235 |  | 173 |  | 35.8 |
International |  | 37 |  | 12 |  | * |  | 79 |  | 29 |  | *
Worldwide |  | 122 |  | 75 |  | 60.8 |  |  | 314 |  | 202 |  | 55.3 |
TECVAYLI |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 115 |  | 105 |  | 9.3 |  |  | 334 |  | 310 |  | 7.5 |
International |  | 62 |  | 30 |  | * |  | 160 |  | 93 |  | 73.0 |
Worldwide |  | 177 |  | 135 |  | 31.3 |  |  | 494 |  | 403 |  | 22.6 |
|  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended
(Dollars in Millions) |  | September 28, 2025 |  | September 29, 2024 |  | Percent Change |  | September 28, 2025 |  | September 29, 2024 |  | Percent Change
ZYTIGA / abiraterone acetate |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 5 |  | 5 |  | (25.0) |  |  | 18 |  | 25 |  | (30.4) |
International |  | 108 |  | 144 |  | (25.1) |  |  | 365 |  | 470 |  | (22.3) |
Worldwide |  | 113 |  | 150 |  | (25.1) |  |  | 383 |  | 496 |  | (22.8) |
OTHER ONCOLOGY |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 56 |  | 36 |  | 54.6 |  |  | 153 |  | 106 |  | 44.8 |
International |  | 39 |  | 50 |  | (22.2) |  |  | 123 |  | 136 |  | (9.7) |
Worldwide |  | 94 |  | 86 |  | 9.7 |  |  | 276 |  | 242 |  | 14.0 |
Immunology |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 2,676 |  | 3,068 |  | (12.8) |  |  | 7,377 |  | 8,499 |  | (13.2) |
International |  | 1,493 |  | 1,552 |  | (3.9) |  |  | 4,492 |  | 5,090 |  | (11.8) |
Worldwide |  | 4,168 |  | 4,621 |  | (9.8) |  |  | 11,868 |  | 13,590 |  | (12.7) |
REMICADE |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 326 |  | 281 |  | 16.2 |  |  | 923 |  | 778 |  | 18.7 |
U.S. Exports |  | 19 |  | 27 |  | (30.9) |  |  | 63 |  | 89 |  | (29.6) |
International |  | 132 |  | 112 |  | 17.7 |  |  | 413 |  | 380 |  | 8.6 |
Worldwide |  | 476 |  | 419 |  | 13.6 |  |  | 1,398 |  | 1,246 |  | 12.2 |
SIMPONI / SIMPONI ARIA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 309 |  | 299 |  | 3.6 |  |  | 906 |  | 820 |  | 10.5 |
International |  | 377 |  | 218 |  | 73.0 |  |  | 1,130 |  | 787 |  | 43.5 |
Worldwide |  | 687 |  | 516 |  | 32.9 |  |  | 2,036 |  | 1,607 |  | 26.7 |
STELARA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,022 |  | 1,770 |  | (42.3) |  |  | 3,081 |  | 5,021 |  | (38.6) |
International |  | 549 |  | 906 |  | (39.4) |  |  | 1,768 |  | 2,991 |  | (40.9) |
Worldwide |  | 1,570 |  | 2,676 |  | (41.3) |  |  | 4,848 |  | 8,012 |  | (39.5) |
TREMFYA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 989 |  | 691 |  | 43.1 |  |  | 2,384 |  | 1,789 |  | 33.3 |
International |  | 434 |  | 316 |  | 37.4 |  |  | 1,181 |  | 932 |  | 26.7 |
Worldwide |  | 1,424 |  | 1,007 |  | 41.3 |  |  | 3,566 |  | 2,721 |  | 31.0 |
OTHER IMMUNOLOGY |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 12 |  | 1 |  | * |  | 21 |  | 3 |  | *
International |  | 0 |  | 0 |  | — |  | 0 |  | 0 |  | —
Worldwide |  | 12 |  | 1 |  | * |  | 21 |  | 3 |  | *
Neuroscience |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,367 |  | 1,094 |  | 25.0 |  |  | 3,712 |  | 3,250 |  | 14.2 |
International |  | 658 |  | 662 |  | (0.7) |  |  | 2,011 |  | 2,090 |  | (3.8) |
Worldwide |  | 2,024 |  | 1,755 |  | 15.3 |  |  | 5,722 |  | 5,340 |  | 7.2 |
CAPLYTA(2) |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 240 |  | — |  | * |  | 451 |  | — |  | *
International |  | — |  | — |  | — |  |  | — |  | — |  | — |
Worldwide |  | 240 |  | — |  | * |  | 451 |  | — |  | *
|  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended
(Dollars in Millions) |  | September 28, 2025 |  | September 29, 2024 |  | Percent Change |  | September 28, 2025 |  | September 29, 2024 |  | Percent Change
CONCERTA / methylphenidate |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 14 |  | 26 |  | (49.2) |  |  | 76 |  | 101 |  | (24.9) |
International |  | 127 |  | 117 |  | 9.0 |  |  | 376 |  | 382 |  | (1.4) |
Worldwide |  | 140 |  | 142 |  | (1.4) |  |  | 452 |  | 482 |  | (6.3) |
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 664 |  | 780 |  | (14.9) |  |  | 2,021 |  | 2,329 |  | (13.2) |
International |  | 267 |  | 269 |  | (0.9) |  |  | 804 |  | 830 |  | (3.1) |
Worldwide |  | 929 |  | 1,049 |  | (11.3) |  |  | 2,824 |  | 3,159 |  | (10.6) |
SPRAVATO |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 405 |  | 243 |  | 67.1 |  |  | 1,047 |  | 660 |  | 58.7 |
International |  | 53 |  | 42 |  | 28.9 |  |  | 146 |  | 120 |  | 21.9 |
Worldwide |  | 459 |  | 284 |  | 61.5 |  |  | 1,193 |  | 780 |  | 53.0 |
OTHER NEUROSCIENCE |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 46 |  | 46 |  | 0.4 |  |  | 119 |  | 161 |  | (26.4) |
International |  | 210 |  | 235 |  | (10.7) |  |  | 684 |  | 759 |  | (9.8) |
Worldwide |  | 256 |  | 281 |  | (8.9) |  |  | 803 |  | 920 |  | (12.7) |
Pulmonary Hypertension |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 815 |  | 815 |  | (0.1) |  |  | 2,358 |  | 2,324 |  | 1.5 |
International |  | 300 |  | 287 |  | 4.8 |  |  | 895 |  | 866 |  | 3.4 |
Worldwide |  | 1,115 |  | 1,102 |  | 1.1 |  |  | 3,253 |  | 3,190 |  | 2.0 |
OPSUMIT/OPSYNVI |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 409 |  | 417 |  | (1.6) |  |  | 1,175 |  | 1,149 |  | 2.3 |
International |  | 168 |  | 166 |  | 1.1 |  |  | 507 |  | 506 |  | 0.2 |
Worldwide |  | 578 |  | 583 |  | (0.8) |  |  | 1,682 |  | 1,655 |  | 1.7 |
UPTRAVI |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 392 |  | 379 |  | 3.5 |  |  | 1,139 |  | 1,120 |  | 1.7 |
International |  | 92 |  | 80 |  | 15.2 |  |  | 272 |  | 232 |  | 17.0 |
Worldwide |  | 484 |  | 458 |  | 5.6 |  |  | 1,411 |  | 1,352 |  | 4.3 |
OTHER PULMONARY HYPERTENSION |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 13 |  | 21 |  | (36.5) |  |  | 44 |  | 56 |  | (21.5) |
International |  | 39 |  | 39 |  | (1.0) |  |  | 116 |  | 127 |  | (8.9) |
Worldwide |  | 53 |  | 60 |  | (13.1) |  |  | 160 |  | 183 |  | (12.7) |
Infectious Diseases |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 326 |  | 365 |  | (10.5) |  |  | 961 |  | 1,023 |  | (6.0) |
International |  | 501 |  | 471 |  | 6.4 |  |  | 1,472 |  | 1,599 |  | (7.9) |
Worldwide |  | 829 |  | 836 |  | (0.9) |  |  | 2,434 |  | 2,622 |  | (7.2) |
EDURANT / rilpivirine |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 7 |  | 8 |  | (7.9) |  |  | 21 |  | 24 |  | (11.8) |
International |  | 378 |  | 323 |  | 16.9 |  |  | 1,082 |  | 926 |  | 16.8 |
Worldwide |  | 385 |  | 330 |  | 16.4 |  |  | 1,103 |  | 950 |  | 16.1 |
|  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended
(Dollars in Millions) |  | September 28, 2025 |  | September 29, 2024 |  | Percent Change |  | September 28, 2025 |  | September 29, 2024 |  | Percent Change
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 315 |  | 355 |  | (11.0) |  |  | 932 |  | 990 |  | (5.8) |
International |  | 81 |  | 94 |  | (13.6) |  |  | 264 |  | 315 |  | (16.1) |
Worldwide |  | 397 |  | 449 |  | (11.6) |  |  | 1,196 |  | 1,305 |  | (8.3) |
OTHER INFECTIOUS DISEASES |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 4 |  | 3 |  | 57.3 |  |  | 8 |  | 10 |  | (11.0) |
International |  | 42 |  | 54 |  | (21.2) |  |  | 126 |  | 358 |  | (64.7) |
Worldwide |  | 47 |  | 56 |  | (17.5) |  |  | 135 |  | 367 |  | (63.3) |
Cardiovascular / Metabolism / Other |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 750 |  | 713 |  | 5.3 |  |  | 2,381 |  | 2,061 |  | 15.5 |
International |  | 149 |  | 170 |  | (13.1) |  |  | 461 |  | 543 |  | (15.2) |
Worldwide |  | 899 |  | 884 |  | 1.7 |  |  | 2,842 |  | 2,605 |  | 9.1 |
XARELTO |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 635 |  | 592 |  | 7.4 |  |  | 1,946 |  | 1,697 |  | 14.7 |
International |  | — |  | — |  | — |  |  | — |  | — |  | — |
Worldwide |  | 635 |  | 592 |  | 7.4 |  |  | 1,946 |  | 1,697 |  | 14.7 |
OTHER |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 115 |  | 121 |  | (5.2) |  |  | 435 |  | 364 |  | 19.4 |
International |  | 149 |  | 170 |  | (13.1) |  |  | 461 |  | 543 |  | (15.2) |
Worldwide |  | 264 |  | 292 |  | (9.8) |  |  | 896 |  | 908 |  | (1.3) |
TOTAL INNOVATIVE MEDICINE |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 9,402 |  | 8,871 |  | 6.0 |  |  | 26,655 |  | 24,993 |  | 6.7 |
International |  | 6,161 |  | 5,709 |  | 7.9 |  |  | 17,983 |  | 17,639 |  | 1.9 |
Worldwide |  | 15,563 |  | 14,580 |  | 6.8 |  |  | 44,638 |  | 42,632 |  | 4.7 |
MEDTECH |  |  |  |  |  |  |  |  |  |  |  |
Cardiovascular |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,306 |  | 1,148 |  | 13.8 |  |  | 3,931 |  | 3,292 |  | 19.4 |
International |  | 908 |  | 819 |  | 10.8 |  |  | 2,698 |  | 2,353 |  | 14.6 |
Worldwide |  | 2,213 |  | 1,966 |  | 12.6 |  |  | 6,629 |  | 5,645 |  | 17.4 |
ELECTROPHYSIOLOGY |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 720 |  | 660 |  | 9.1 |  |  | 2,145 |  | 2,057 |  | 4.3 |
International |  | 698 |  | 619 |  | 12.6 |  |  | 2,064 |  | 1,889 |  | 9.2 |
Worldwide |  | 1,418 |  | 1,279 |  | 10.8 |  |  | 4,209 |  | 3,946 |  | 6.7 |
ABIOMED |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 336 |  | 293 |  | 14.5 |  |  | 1,035 |  | 905 |  | 14.3 |
International |  | 86 |  | 68 |  | 26.8 |  |  | 256 |  | 207 |  | 23.9 |
Worldwide |  | 423 |  | 362 |  | 16.8 |  |  | 1,291 |  | 1,112 |  | 16.1 |
SHOCKWAVE(3) |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 220 |  | 163 |  | 34.4 |  | 659 |  | 240 |  | *
International |  | 59 |  | 66 |  | (11.2) |  | 169 |  | 66 |  | *
Worldwide |  | 278 |  | 229 |  | 21.2 |  | 828 |  | 306 |  | *
|  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended
(Dollars in Millions) |  | September 28, 2025 |  | September 29, 2024 |  | Percent Change |  | September 28, 2025 |  | September 29, 2024 |  | Percent Change
OTHER CARDIOVASCULAR |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 30 |  | 30 |  | 0.0 |  |  | 93 |  | 89 |  | 4.2 |
International |  | 65 |  | 66 |  | (1.0) |  |  | 209 |  | 192 |  | 9.0 |
Worldwide |  | 95 |  | 96 |  | (0.7) |  |  | 302 |  | 281 |  | 7.5 |
Orthopaedics |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,396 |  | 1,359 |  | 2.7 |  |  | 4,200 |  | 4,229 |  | (0.7) |
International |  | 878 |  | 832 |  | 5.6 |  |  | 2,620 |  | 2,614 |  | 0.3 |
Worldwide |  | 2,274 |  | 2,191 |  | 3.8 |  |  | 6,820 |  | 6,843 |  | (0.3) |
HIPS |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 262 |  | 250 |  | 4.7 |  |  | 796 |  | 785 |  | 1.3 |
International |  | 144 |  | 131 |  | 9.7 |  |  | 440 |  | 435 |  | 1.2 |
Worldwide |  | 405 |  | 381 |  | 6.4 |  |  | 1,235 |  | 1,220 |  | 1.3 |
KNEES |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 216 |  | 212 |  | 2.1 |  |  | 673 |  | 684 |  | (1.5) |
International |  | 160 |  | 140 |  | 14.3 |  |  | 482 |  | 463 |  | 4.0 |
Worldwide |  | 377 |  | 352 |  | 7.0 |  |  | 1,155 |  | 1,147 |  | 0.7 |
TRAUMA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 512 |  | 497 |  | 3.0 |  |  | 1,515 |  | 1,499 |  | 1.1 |
International |  | 281 |  | 265 |  | 6.4 |  |  | 818 |  | 786 |  | 4.1 |
Worldwide |  | 793 |  | 761 |  | 4.2 |  |  | 2,333 |  | 2,285 |  | 2.1 |
SPINE, SPORTS & OTHER |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 406 |  | 400 |  | 1.3 |  |  | 1,216 |  | 1,262 |  | (3.7) |
International |  | 293 |  | 296 |  | (1.1) |  |  | 881 |  | 930 |  | (5.3) |
Worldwide |  | 698 |  | 696 |  | 0.3 |  |  | 2,096 |  | 2,191 |  | (4.3) |
Surgery |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,031 |  | 983 |  | 4.9 |  |  | 3,076 |  | 2,965 |  | 3.8 |
International |  | 1,511 |  | 1,451 |  | 4.1 |  |  | 4,417 |  | 4,373 |  | 1.0 |
Worldwide |  | 2,542 |  | 2,434 |  | 4.4 |  |  | 7,493 |  | 7,338 |  | 2.1 |
ADVANCED |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 477 |  | 448 |  | 6.2 |  |  | 1,411 |  | 1,360 |  | 3.7 |
International |  | 688 |  | 661 |  | 4.2 |  |  | 1,991 |  | 1,977 |  | 0.7 |
Worldwide |  | 1,165 |  | 1,109 |  | 5.0 |  |  | 3,402 |  | 3,337 |  | 1.9 |
GENERAL |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 555 |  | 535 |  | 3.8 |  |  | 1,666 |  | 1,605 |  | 3.8 |
International |  | 823 |  | 791 |  | 4.0 |  |  | 2,426 |  | 2,397 |  | 1.2 |
Worldwide |  | 1,378 |  | 1,325 |  | 3.9 |  |  | 4,092 |  | 4,001 |  | 2.3 |
Vision |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 571 |  | 549 |  | 4.2 |  |  | 1,694 |  | 1,619 |  | 4.7 |
International |  | 828 |  | 751 |  | 10.2 |  |  | 2,354 |  | 2,224 |  | 5.8 |
Worldwide |  | 1,400 |  | 1,300 |  | 7.7 |  |  | 4,048 |  | 3,843 |  | 5.3 |
|  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended
(Dollars in Millions) |  | September 28, 2025 |  | September 29, 2024 |  | Percent Change |  | September 28, 2025 |  | September 29, 2024 |  | Percent Change
CONTACT LENSES / OTHER |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 456 |  | 441 |  | 3.5 |  |  | 1,337 |  | 1,288 |  | 3.8 |
International |  | 562 |  | 527 |  | 6.6 |  |  | 1,565 |  | 1,508 |  | 3.8 |
Worldwide |  | 1,018 |  | 968 |  | 5.2 |  |  | 2,902 |  | 2,796 |  | 3.8 |
SURGICAL |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 116 |  | 108 |  | 7.0 |  |  | 358 |  | 331 |  | 8.0 |
International |  | 266 |  | 225 |  | 18.7 |  |  | 789 |  | 717 |  | 10.1 |
Worldwide |  | 383 |  | 333 |  | 14.9 |  |  | 1,147 |  | 1,048 |  | 9.4 |
TOTAL MEDTECH |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 4,306 |  | 4,038 |  | 6.6 |  |  | 12,902 |  | 12,105 |  | 6.6 |
International |  | 4,124 |  | 3,853 |  | 7.0 |  |  | 12,089 |  | 11,564 |  | 4.5 |
Worldwide |  | 8,430 |  | 7,891 |  | 6.8 |  |  | 24,991 |  | 23,669 |  | 5.6 |
WORLDWIDE |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 13,708 |  | 12,909 |  | 6.2 |  |  | 39,557 |  | 37,098 |  | 6.6 |
International |  | 10,285 |  | 9,562 |  | 7.6 |  |  | 30,072 |  | 29,203 |  | 3.0 |
Worldwide |  | $23,993 |  | 22,471 |  | 6.8 | % |  | $69,629 |  | 66,301 |  | 5.0 | %
* Percentage greater than 100% or not meaningful (1) Includes the sales of RYBREVANT and RYBREVANT + LAZCLUZE (2) Acquired with the Intra-Cellular Therapies acquisition on April 2, 2025 (3) Due to the timing of the integration of the US and foreign affiliates in the year of acquisition (2024), prior quarter (Q3 2024) Shockwave International revenue includes approximately $20 million of sales that should be reflected in the U.S. business. Year-to-date and total Shockwave sales are not impacted, and the amount was immaterial to recast prior year reporting Subsequent to the quarter, on October 14, 2025, the Company announced its intention to separate its Orthopaedics business. The Company intends to explore multiple paths to effect the planned separation with a targeted completion within 18 to 24 months after the initial announcement. Segment income before tax
|  | Fiscal Third Quarter Ended |  |
(Dollars in Millions) |  | September 28, 2025 |  | September 29, 2024 |  |  |  |  |  |  |  |  |  |  |
|  | Innovative Medicine(1) | MedTech(2) | Total |  | Innovative Medicine(1) | MedTech(2) | Total |  |  |  |  |  |  |  |  |  |  |
Sales to customers |  | $15,563 | 8,430 |  |  | 14,580 | 7,891 |  |  |  |  |  |  |  |  |  |  |  |
Cost of products sold |  | 3,672 | 3,612 |  |  | 3,549 | 3,381 |  |  |  |  |  |  |  |  |  |  |  |
Selling, marketing and administrative |  | 2,869 | 2,801 |  |  | 2,491 | 2,723 |  |  |  |  |  |  |  |  |  |  |  |
Research and development expense |  | 2,944 | 728 |  |  | 4,213 | 739 |  |  |  |  |  |  |  |  |  |  |  |
Other segment items (3) |  | (368) | 2 |  |  | (155) | (11) |  |  |  |  |  |  |  |  |  |  |  |
Segment income before tax |  | $6,446 | 1,287 | 7,733 |  | 4,482 | 1,059 | 5,541 |  |  |  |  |  |  |  |  |  |  |
(Income)/Expense not allocated to segments (4) |  |  |  | 240 |  |  |  | 2,203 |  |  |  |  |  |  |  |  |  |  |
Earnings before provision for taxes on income |  |  |  | $7,493 |  |  |  | $3,338 |  |  |  |  |  |  |  |  |  |  |
|  | Fiscal Nine Months Ended |  |  |  |  |  |  |  |  |  |
Sales to customers |  | $44,638 | 24,991 |  |  | 42,632 | 23,669 |  |  |  |  |  |  |  |  |  |  |  |
Cost of products sold |  | 11,670 | 10,576 |  |  | 10,522 | 9,749 |  |  |  |  |  |  |  |  |  |  |  |
Selling, marketing and administrative |  | 7,919 | 8,319 |  |  | 7,594 | 7,976 |  |  |  |  |  |  |  |  |  |  |  |
Research and development expense |  | 8,361 | 2,052 |  |  | 9,831 | 2,103 |  |  |  |  |  |  |  |  |  |  |  |
Other segment items (3) |  | (520) | 132 |  |  | (225) | 173 |  |  |  |  |  |  |  |  |  |  |  |
Segment income before tax |  | $17,208 | 3,912 | 21,120 |  | 14,910 | 3,668 | 18,578 |  |  |  |  |  |  |  |  |  |  |
(Income)/Expense not allocated to segments (4) |  |  |  | (6,495) |  |  |  | 5,778 |  |  |  |  |  |  |  |  |  |  |
Earnings before provision for taxes on income |  |  |  | $27,615 |  |  |  | $12,800 |  |  |  |  |  |  |  |  |  |  |
(1) Innovative Medicine includes: •Intangible amortization expense of $0.6 billion and $0.7 billion in the fiscal third quarter of 2025 and 2024, respectively. Intangible amortization expense of $2.0 billion and $2.1 billion in the fiscal nine months of 2025 and 2024, respectively. •Acquisition and integration related expense of $0.1 billion and $0.3 billion in the fiscal third quarter and fiscal nine months of 2025, respectively, primarily related to the Intra-Cellular acquisition. •Expense of $1.25 billion to secure the global rights to the NM26 bispecific antibody (Yellow Jersey acquisition) in the fiscal third quarter and fiscal nine months of 2024. •Litigation expense of $0.4 billion in both the fiscal third quarter and fiscal nine months of 2024, primarily related to Risperdal Gynecomastia. •Monetization of royalty rights of $0.3 billion in the fiscal third quarter and fiscal nine months of 2024. •An In-process research and development impairment of $0.2 billion in the fiscal nine months of 2024 associated with the M710 (biosimilar) asset acquired from Momenta in 2020. •A restructuring related charge of $0.1 billion in the fiscal nine months of 2024. (2) MedTech includes: •Intangible amortization expense of $0.5 billion in both the fiscal third quarter of 2025 and 2024. Intangible amortization expense of $1.4 billion and $1.3 billion in the fiscal nine months of 2025 and 2024, respectively. •Acquisition and integration related net expense of $0.1 billion and $0.2 billion in the fiscal third quarter and fiscal nine months of 2025, respectively. Acquisition and integration related expense of $0.3 billion and $0.9 billion, in the fiscal third quarter and fiscal nine months of 2024, respectively, primarily driven by the Shockwave acquisition. •A gain on the sale of securities of $0.2 billion in the fiscal third quarter and fiscal nine months of 2025 •A gain of $0.2 billion related to the Acclarent divestiture in the fiscal nine months of 2024. •A restructuring related charge of $0.2 billion and $0.3 billion in both the fiscal third quarter and fiscal nine months of 2025. A restructuring related charge of $0.1 billion in the fiscal nine months of 2024. Refer to Note 12 for additional details. (3) Other segment expenses for each reportable segment include charges related to other income and expense, restructuring activities and impairment charges related to in-process research and development. (4) Amounts not allocated to segments include interest (income)/expense and general corporate (income)/expense. The fiscal nine months of 2025 includes the reversal of approximately $7.0 billion, a significant portion of the previously accrued talc reserve. The fiscal third quarter and fiscal nine months of 2024 includes charges for talc matters of $2.0 billion and $5.1 billion, respectively. For additional details related to talc refer to Note 11 to the Consolidated Financial Statements. The fiscal nine months of 2024 includes a loss of approximately $0.4 billion related to the debt to equity exchange of the Company's remaining shares of Kenvue Common Stock.
|  | Identifiable Assets
(Dollars in Millions) |  | September 28, 2025 |  | December 29, 2024
Innovative Medicine |  | $74,422 |  | 57,070
MedTech |  | 86,502 |  | 84,322
Total |  | 160,924 |  | 141,392
General corporate (1) |  | 31,892 |  | 38,712
Worldwide total |  | $192,816 |  | 180,104
(1)General corporate includes cash, cash equivalents, marketable securities and other corporate assets.
|  | Additions to Property, Plant & Equipment |  | Depreciation and Amortization
|  | Fiscal Nine Months Ended
(Dollars in Millions) |  | September 28, 2025 |  | September 29, 2024 |  | September 28, 2025 |  | September 29, 2024
Innovative Medicine |  | $1,166 |  | 971 |  | $2,757 |  | 2,793
MedTech |  | 1,674 |  | 1,629 |  | 2,564 |  | 2,370
Segments total |  | 2,840 |  | 2,600 |  | 5,321 |  | 5,163
General corporate |  | 155 |  | 212 |  | 171 |  | 280
Worldwide total |  | $2,995 |  | 2,812 |  | $5,492 |  | 5,443
Sales by geographic area
|  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended
(Dollars in Millions) |  | September 28, 2025 |  | September 29, 2024 |  | Percent Change |  | September 28, 2025 |  | September 29, 2024 |  | Percent Change
United States |  | $13,708 |  | 12,909 |  | 6.2 | % |  | $39,557 |  | 37,098 |  | 6.6 | %
Europe |  | 5,440 |  | 4,914 |  | 10.7 |  |  | 15,937 |  | 15,291 |  | 4.2 |
Western Hemisphere, excluding U.S. |  | 1,231 |  | 1,173 |  | 4.9 |  |  | 3,604 |  | 3,579 |  | 0.7 |
Asia-Pacific, Africa |  | 3,614 |  | 3,475 |  | 4.0 |  |  | 10,531 |  | 10,333 |  | 1.9 |
Total |  | $23,993 |  | 22,471 |  | 6.8 | % |  | $69,629 |  | 66,301 |  | 5.0 | %

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 14: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 16: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContent Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26 Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration